WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

WELL

194.67

-0.53%↓

PLD

130.22

+1.85%↑

EQIX

966.84

+0.85%↑

AMT

176.22

-0.23%↓

SPG

181.62

-1.56%↓

Search

Dynex Capital Inc

Gesloten

SectorVastgoed

12.41 0.08

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.24

Max

12.55

Belangrijke statistieken

By Trading Economics

Inkomsten

35M

185M

Verkoop

38M

177M

K/W

Sectorgemiddelde

5.29

67.236

EPS

0.22

Dividendrendement

15.31

Winstmarge

104.701

Werknemers

28

EBITDA

169M

319M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.08% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

15.31%

6.64%

Volgende Winsten

20 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

499M

2.7B

Vorige openingsprijs

12.33

Vorige sluitingsprijs

12.41

Nieuwssentiment

By Acuity

50%

50%

61 / 167 Rangschikking in Real estate

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Dynex Capital Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Dynex Capital Inc Prognose

Koersdoel

By TipRanks

23.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.25 USD  23.08%

Hoogste 15.25 USD

Laagste 15.25 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Dynex Capital Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

10.785 / 11.125Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

61 / 167 Rangschikking in Vastgoed

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Dynex Capital Inc

Dynex Capital, Inc., a mortgage real estate investment trust, invests in mortgage-backed securities (MBS) on a leveraged basis in the United States. It invests in agency and non-agency MBS consisting of residential MBS, commercial MBS (CMBS), and CMBS interest-only securities. Agency MBS have a guaranty of principal payment by an agency of the U.S. government or a U.S. government-sponsored entity, such as Fannie Mae and Freddie Mac. Non-Agency MBS have no such guaranty of payment. The company has qualified as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal income taxes if it distributes at least 90% of its taxable income to its stockholders as dividends. Dynex Capital, Inc. was incorporated in 1987 and is headquartered in Glen Allen, Virginia.
help-icon Live chat